| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 61,236 | 183,105 | ||
| Restricted cash | 42 | 42 | ||
| Total cash, cash equivalents and restricted cash | 61,278 | 183,147 | ||
| Short-term investments | 149,540 | - | ||
| Accounts and other receivables | 845 | 321 | ||
| Income tax and r&d incentive receivables | 547 | 557 | ||
| Prepaid expenses and other current assets | 4,405 | 4,397 | ||
| Total current assets | 216,615 | 188,422 | ||
| Property and equipment, net | 337 | 364 | ||
| Other assets | 1,495 | 1,564 | ||
| Total assets | 218,447 | 190,350 | ||
| Accounts payable | 4,804 | 851 | ||
| Accrued expenses and other current liabilities | 7,802 | 8,369 | ||
| Total current liabilities | 12,606 | 9,220 | ||
| Term loan, noncurrent | 14,445 | 14,332 | ||
| Other noncurrent liabilities | 5,795 | 5,431 | ||
| Total liabilities | 32,846 | 28,983 | ||
| Common stock, 0.0001 par value 200,000,000 shares authorized 95,598,665 and 72,352,701 shares issued and outstanding as of september 30, 2025 and december 31 2024, respectively | 10 | 9 | ||
| Additional paid-in capital | 812,732 | 769,508 | ||
| Accumulated deficit | -622,125 | -603,111 | ||
| Accumulated other comprehensive loss, net | -5,016 | -5,039 | ||
| Total stockholders' equity | 185,601 | 161,367 | ||
| Total liabilities and stockholders' equity | 218,447 | 190,350 | ||
Altimmune, Inc. (ALT)
Altimmune, Inc. (ALT)